Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Innate Pharma obtains ISO9001:2000 certification for its R&D activity in the field of immunotherapy

Marseille, September 2, 2005 - Innate Pharma, a leading developer of novel anti-tumoral therapies, announced today that it has received ISO9001:2000 certification for its research and development activity in the field of immunotherapy.

This certification marks a new milestone in Innate Pharma's development and occurs at a time when the company is significantly building up its team, enlarging its portfolio of compounds and working on a number of new industry partnerships.

'The ISO9001:2000 certification is undoubtedly a major step forward in Innate Pharma's path to becoming a mature company,' said Hervé Brailly, CEO at Innate Pharma. 'It will be a key asset in winning future industrial and commercial contracts with the pharmaceutical industry.'

'European biotechnology companies that have sought and obtained this certification are few and far between,' said Jacques Beslin, Managing Director of the French certification body AFAQ AFNOR. 'Innate Pharma can be proud of having been through the certification procedure successfully. The award confirms the company's ability to compete on a global scale and that it achieves the tough quality criteria defined by the ISO standard.'

About Innate Pharma:
Innate Pharma S.A.S., is a French biopharmaceutical company specialized in cancer immuno-therapeutics. It is the first company to develop immuno-modulating agents targeting non-conventional lymphocytes. The company already has several drug candidates in clinical development, including two products in Phase I of clinical development in cancer. The company was founded in 1999, and has raised EUR40 million in private funding since its inception in three rounds of financing. Companies investing in Innate are Novo-Nordisk (Copenhagen), NIF (Tokyo), Quilvest (Paris), Sofinnova Partners (Paris), Alta Partners (San Francisco), GIMV (Anvers), Auriga Partners (Paris), Axa Private Equity (Paris), Gilde Biotech & Nutrition (Utrecht), Pechel Industries (Paris), Innoveris (Marseille) et Inserm-Transfert (Paris). Based in Marseille, Innate Pharma employs 50 staff.

Publisher Contact Information:

Innate Pharma
+44 (0)1273 675100

Company profile of Innate Pharma
Past press releases of Innate Pharma.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.